BLEEDING, THROMBOSIS AND VASCULAR BIOLOGY
The Official Journal of the Italian Society for the Study of Hemostasis and Thrombosis
SISET
Società Italiana per lo Studio dell'Emostasi e Trombosi
Editor-in-Chief: Giovanni de Gaetano, Italy | eISSN: 2785-5309

Vol 4, No 3 (2025)
DOI: 10.4081/btvb.2025.372

SUPPLEMENTARY MATERIAL

Table S1. Responses expressed as percentage of the first section of the survey from the 19 participating hemophilia treatment centers.

Does your center treat patients with rare bleeding disorders?	a) Of all ages b) Pediatric only c) Predominantly adults	**84.2%** **5.3%** **10.5%**
How many years have you been treating patients with rare bleeding disorders?	a) Less than 5 years b) Between 5 and 20 years c) More than 20 years	**0** **55%** **45%**
Does your center provide consulting services to other departments in your hospital or in other hospitals for patients with rare bleeding disorders?	a) Yes b) No	**100%** **0**
Does your center have experience with patients undergoing prophylaxis for rare bleeding disorders?	a) Yes b) No	**100%** **0**
Do you think that standard screening tests (PT, aPTT, Fbg) can rule out the presence of a mild coagulation factor defect?	a) Yes b) No c) I don't know	**0** **100%** **0**
Do you think that, when diagnosing a coagulation factor defect, it is necessary to determine antigen levels as well as functional dosage?	a) Yes, always b) Yes, in selected cases c) No	**11.1 %** **77.8%** **11.1%**
Do you think that in a subject with a known diagnosis of rare bleeding disorder it is appropriate to investigate the possible concomitant presence of other hemostasis defects (von Willebrand disease, functional platelet defects) to determine the bleeding risk profile?	a) Yes b) No c) I don't know	**83.4 %** **16.6%** **0**

PT, prothrombin time; aPTT, activated partial thromboplastin time; Fbg, fibrinogen.